Abstract:Phenylalanine hydroxylase (PAH) deficient phenylketonuria (PKU) is rightfully considered the paradigm treatable metabolic disease. Dietary substrate restriction (i.e. phenylalanine (Phe) restriction) was applied >60 years ago and remains the primary PKU management means. The traditional model of PKU neuropathophysiology dictates blood Phe over-representation directs asymmetric blood:brain barrier amino acid transport through the LAT1 transporter with subsequent increased cerebral Phe concentration and low concentrations of tyrosine (Tyr), tryptophan (Trp), leucine (Leu), valine (Val), and isoleucine (Ile). Low Tyr and Trp concentrations generate secondary serotonergic and dopaminergic neurotransmitter paucities, widely attributed as drivers of PKU neurologic phenotypes. White matter disease, a central PKU characteristic, is ascribed to Phe-mediated tissue toxicity. Impaired cerebral protein synthesis, by reduced concentrations of non-Phe large neutral amino acids, is another cited pathological mechanism. The PKU amino acid transport model suggests Phe management should be more efficacious than is realized, as even early identified, continuously treated patients that retain therapy compliance into adulthood, demonstrate neurologic disease elements. Reduced cerebral metabolism was an early-recognized element of PKU pathology. Legacy data (late 1960's to mid-1970's) determined the Phe catabolite phenylpyruvate inhibits mitochondrial pyruvate transport. Respirometry of Pahenu2 cerebral mitochondria have attenuated respiratory chain complex 1 induction in response to pyruvate substrate, indicating reduced energy metabolism. Oxidative stress is intrinsic to PKU and Pahenu2 brain tissue presents increased reactive oxygen species. Phenylpyruvate inhibits glucose-6-phosphate dehydrogenase that generates reduced niacinamide adenine dinucleotide phosphate the obligatory cofactor of glutathione reductase. Pahenu2 brain tissue metabolomics identified increased oxidized glutathione and glutathione disulfide. Over-represented glutathione disulfide argues for reduced glutathione reductase activity secondary to reduced NADPH. Herein, we review evidence of energy and oxidative stress involvement in PKU pathology. Data suggests energy deficit and oxidative stress are features of PKU pathophysiology, providing intervention-amenable therapeutic targets to ameliorate disease elements refractory to standard of care.

Hyperactive GluN2B impairs neuroplasticity and cognition in phenylketonuria

AMP-activated Protein Kinase Activation in Mediating Phenylalanine-Induced Neurotoxicity in Experimental Models of Phenylketonuria.

Phenylketonuria and the brain

Pitfalls in the Management of Phenylketonuria in China

Transcriptome Profiling of Phenylalanine-Treated Human Neuronal Model: Spotlight on Neurite Impairment and Synaptic Connectivity

Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria

Phenylketonuria-related cognitive dysfunction and its mechanism in a BTBR-Pahenu 2 mouse model

Effects of Phenylalanine on the Survival and Neurite Outgrowth of Rat Cortical Neurons in Primary Cultures: Possible Involvement of Brain-Derived Neurotrophic Factor

Metabolomics Analysis Reveals Perturbations of Cerebrocortical Metabolic Pathways in the Pahenu2 Mouse Model of Phenylketonuria.

Efficacy and Safety of a Phenylalanine-Free Amino Acid-Based Enteral Formula (AA-PKU2) in 1-8 Year-Old Children with Phenylketonuria: a Prospective, Open, Self-Controlled and Multi-Center Study in China

High phenylalanine concentrations induce demyelination and microglial activation in mouse cerebellar organotypic slices

Phenylketonuria oxidative stress and energy dysregulation: Emerging pathophysiological elements provide interventional opportunity

Phenylketonuria-related Synaptic Changes in a BTBR-Pah Enu2 Mouse Model

Effects of Phenylalanine and Its Metabolites on Cytoplasmic Free Calcium in Cortical Neurons

Effect of a four-week oral Phe administration on neural activation and cerebral blood flow in adults with early-treated phenylketonuria

Gene Expression Profiles in the Brain of Phenylketonuria Mouse Model Reversed by the Low Phenylalanine Diet Therapy

A Study of Gene Expression Profiles of Cultured Embryonic Rat Neurons Induced by Phenylalanine

Enhancing GluN2A-type NMDA receptors impairs long-term synaptic plasticity and learning and memory

White matter disturbances in phenylketonuria: Possible underlying mechanisms

Study on brain delayed myelination and blood phenylalanine of patients with phenylketonuria

Differential Effects of Phenylalanine on Rac1, Cdc42, and RhoA Expression and Activity in Cultured Cortical Neurons